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Background: Kisspeptin (Kisspeptin-54; KP-54) is a 54-amino acid peptide was originally known as
metastin that was implicated in suppression of tumor metastasis and circulating kisspeptin has been
proposed as a tumor marker for numerous cancers in humans. However, the plasma level of KP-54 in
gastric cancer (GC) remains undetermined.
Aim: We aimed to investigate the plasma levels of KP-54 in patients with GC.
Methods: Plasma KP-54 levels were quantiﬁed with enzyme-immunoassay from blood samples of 40
patients with GC at their initial staging and 59 age-matched controls.
Results: Plasma KP-54 levels were signiﬁcantly higher in GC patients (63.3  17.9) than in controls
(49.0  12.7) (p ¼ 0.000). Cut-off value for KP-54 was determined as 44 ng/ml and sensitivity, speciﬁcity,
positive predictive value and negative predictive value, were 60%, 78%, 63%, and 74% respectively. Plasma
KP-54 levels were not correlated with any clinicopathological features of GC patients (p > 0.05).
Conclusions: Result of our preliminary study suggest that plasma KP-54 levels might be a useful
parameter in diagnosis of GC.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gastric cancer (GC) is the fourth most common human malig-
nant disease and second leading cause of cancer related death in
both sexes worldwide.1 Even though endoscopic examination is the
most reliable method for the screening of GC, the feasibility and
cost-effectiveness of this invasive approach in most countries
except Japan remain questionable because of the lower incidence
rates of disease.2 A simple diagnostic test, such as a plasma
biomarker assay might facilitate screening for GC.
Kisspeptin-543 encoded by KiSS-1 gene was identiﬁed as
a humanmetastasis-suppressor gene in 1997 at breast cancer cells4
and in 2001 at melanoma cells.5 The endogenous ligand was
initially called metastin, and now is referred to as Kisspeptin-54
(KP-54) after its role as a suppressor in metastasis was identi-
ﬁed.6 Circulating KP-54 has been proposed as a tumor marker for
numerous cancers in humans. Prior to our study, elevated levels of
plasma metastin-L1 (KP-54) have been reported in patients with
pancreatic cancer7 and colorectal cancer.8 It has also been reportedgery, Tokushukai Hospital, 4-
apan. Tel.: þ81 72 445 9915;
nbay@gmail.com (E. Canbay).
ciates Ltd. Published by Elsevier Ltthat high plasma and tissue levels of KP-54 were associated with
good prognosis in patients with pancreatic cancer.9 In this study,
we aimed to determine the plasma KP-54 levels in patients with GC.
2. Materials and methods
2.1. Patients and controls
Forty caucasian GC patients at their initial staging admitted to Istanbul
University of Turkey, Istanbul Medical Faculty, Gastrointestinal Surgery Services and
59 caucasian age-matched healthy controls were enrolled in the study between
March 2009 and June 2010. All patients had histologically conﬁrmed GC and their
relevant clinicopathological details were obtained prospectively from our patients’
records.
2.2. Preparation of plasma samples
All blood samples were collected in tubes containing 1 mg/ml EDTA-2Naþ,
centrifuged at 1600  g for 25 min at 4 C, and then stored at 80 C until assay.
2.3. Enzyme immunoassay (EIA) procedure for KP-54
Peptide levels in plasma were measured using highly sensitive enzyme immu-
noassay (EIA) for KP-54, that has been described previously.10 Assays were performed
using highly sensitive human Metastin- (1-54)-amide two sites EIA kit (EK-048-59)
was purchased from the Phoenix Pharmaceuticals (Belmont, CA, USA), after extraction
with Phoenix Peptide sep-columns (RK-Sepcol-2). The minimum detectable concen-
trationwas 5 ng/ml. The intra-assay variation and inter-assay variationwere<4% andd. All rights reserved.
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Fig. 1. Receiver operating characteristic (ROC) curve for KP-54. (The best cut-off value
is 44 ng/ml). Area under the ROC curve (AUC) is 0.725; Standard Errora (a DeLong et al.,
1988(18)): 0.054; 95% CIb (b Binomial exact): 0.627e0.810; Z statistic: 4.188, signiﬁ-
cance level P ¼ 0.000.
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with a secondary antibody and the nonspeciﬁc binding sites were blocked. The
secondary antibody bound to the Fc fragment of the primary antibody (peptide
antibody), whose Fab fragment competitively bound by both biotinylated peptide and
peptide standard or targeted peptide in samples. The biotinylated peptide interacted
with streptavidine horseradish peroxidase (SAeHRP) that catalyzes the substrate. The
intensity of the yellow was directly proportional to the amount of biotinylated
peptideeSAeHRP complex but inversely proportional to the amount of the peptide in
standard solutions or samples. Absorbance was read at 420 nm.
2.4. Statistical analysis
All data obtained from patients and controls were evaluated by using SPSS ver.
13.0 (SPSS Inc., Chicago, IL, USA) and MedCalc-version 11.5.1 (MedCalc Software free
trial, Mariakerke, Belgium). Values are presented as the mean  standard deviation
ormedian SEM. In comparison of groups, Student t-test, one-way variance analysis
(ANOVA) followed by Tukey HSD Post Hoc tests, Spearman’s correlation analysis, c2
analysis or, when appropriate, the Fisher exact test, Mann Whitney U-test, and the
Kruskal Wallis tests were used. Repeated measures analysis of variance was used to
analyze changes in variables over time. Receiver operator characteristic (ROC)
analyses were used to determine the cut-off value, speciﬁcity and sensitivity of KP-
54.11 Non-parametric Spearman’s R correlation coefﬁcients were computed to
analyze the relationship between plasma KP-54 levels and different clinical param-
eters (e.g. tumor stage and grade). A p-value of <0.05 was considered signiﬁcant.
3. Results
Patients and primary tumor characteristics are shown in
Table 1. Total plasma KP-54 levels that were below the level of
detection were assumed to be 5 ng/ml for statistical analysis. The
median plasma KP-54 was 63.3  17.9 ng/ml for GC patients
(n ¼ 40) and 49  12.7 ng/ml for controls (n ¼ 59) (Mann Whitney
U, p ¼ 0.000). Data of plasma KP-54 levels were analyzed by ROC
curve (Fig. 1) and area under the curve (AUC) was determined to
be 0.725  0.054 (95% conﬁdence interval (CI):0.627e0.810;
p < 0.0001) (24). The best cut-off value of KP-54 levels accord-
ing to our study group was selected as 44 ng/ml according to ROC
curve analysis (Fig. 2). When we take the cut-off value as 44 ng/ml,
24 of 40 (60%) GC patients had their plasma KP-54 levels equal to
or above that concentration; whereas 46 of 59 (78%) controls had
KP-54 levels below 44 ng/ml. Sensitivity, speciﬁcity, PPV and NPV
for the cut-off value of 44 ng/ml were 60%, 78%, 63.1%, and 73.7%,Table 1
Characteristics of GC patients and controls. Data are presented as mean  SD.
p<0.05;was considered signiﬁcantly difference betweenpatients and control group.
Parameters Patients
(n ¼ 40) (%)
Controls
(n ¼ 59) (%)
P value
Mean age, yearsSD 58.05  13.4 57.1  7.44 0.670
Gender
Male 26 (65%) 30 (50.8%)
Female 14 (35%) 29 (49.2%) 0.117
Differantiation
Well 8 (20%)
Moderately 23 (57.5%)
Poor 9 (22.5%)
Tumor size
T1 2 (5%)
T2 7 (17.5%)
T3 25 (62.5%)
T4 6 (15%)
Nodal involvement
N0 7 (17.5%)
N1 7 (17.5%)
N2 26 (65%)
Stages
Stage 1 4 (10%)
Stage 2 11 (27.5%)
Stage 3 11 (27.5%)
Stage 4 14 (35%)
Metastasesþ direct invasion
No 14 (35%)
Yes 26 (65%)respectively. When we calculated likelihood ratios (LR), positive LR
was 2.53 and negative LR was 0.52 for our plasma cut-off value of
KP-54 level.
Correlation analysis was performed using Spearman correlation
test in order to determine whether plasma KP-54 levels changed in
terms of clinicopathological ﬁndings such as tumor size, lymph
node involvement, tumor grades, distant metastases and stages.
Plasma KP-54 levels greater than 44 ng/ml were found to be not
correlated with any of the clinicopathological parameters of
patients with GC (p > 0.05, Table 2).4. Discussion
GC has a complex network of molecular alterations along its
carcinogenesis pathway and is diagnosed at advanced stages in the
majority of cases. Despite numerous studies focused on these
issues, many crucial questions and early diagnosis with convenient
diagnostic tools of GC still remain to be clariﬁed. Therefore, one of
the most important requirements for GC is that the necessity of0
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Fig. 2. Cut-off value of plasma Kisspeptin-54 (KP-54) levels. When 44 ng/ml was
selected as cut-off value, 78% of controls had plasma KP-54 levels below 44 ng/ml, and
60% of GC had plasma KP-54 levels above 44 ng/ml.
Table 2
No correlation was detected between plasma KP-54 levels and patients’ cahar-
acteristics. P < 0.05 was considered to be signiﬁcant.
Clinicopathologic
characteristics of
GC patients
KP-54 (ng/ml)
>44 (n ¼ 24) <44 (n ¼ 16) P
Age
<60 14 6 0.206
60 10 10
Sex
Male 17 9 0.356
Female 7 7
Differentiation
Poor 3 6 0.441
Moderately 17 6
Well 4 4
Primary tumor size
T1 1 1 0.938
T2 5 2
T3 14 11
T4 2 4
Lymph node metastasis
N0 12 6 0.863
N1 6 1
N2 8 9
Distant metastasis
Present 7 7 0.356
Absent 17 9
Stages
Stage I 1 3 0.410
Stage II 10 1
Stage III 6 5
Stage IV 7 7
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markers for detection of GC at earlier stages.
Our study is the ﬁrst report on investigations of plasma KP-54
levels in GC that demonstrates the plasma KP-54 levels are signif-
icantly increased in patients with GC at their initial diagnosis
compared with control group supporting diagnostic value of
plasma KP-54 in GC. Even though signiﬁcantly elevated plasma KP-
54 levels were detected in our GC patients, we have not observed
that KP-54 was associated with any clinicopathological parameters
of these patients. For GC, Dhar et al.12 showed that GC with low
KiSS-1 had frequent venous invasion, distant metastasis and tumor
recurrence. Guan-Zhen et al.13 detected that reduced KiSS-1
expression in lymph node and liver metastases compared with
primary tumours of GC.
There are several limitations that need to be addressed
regarding the present study. The ﬁrst limitation concerns the vali-
dation set of ELISA with immunohistochemistry or RT-PCR has not
included in the study. A prospective clinical trial study including
comparison of plasma expression with using other techniques will
better assess the performance of our assay. The second limitation is
that size of the study groups who needs to be enlarged with long-
term follow up. Longer follow-up in big study size group will give
more information regarding the prognostic value of plasma KP-54
in GC patients. The population of normal volunteers included
blood donors who are selected for not presenting any symptom or
acute disease that they may have an occult or undiagnosed disease
during the sample collections. Further validationwill need to select
negative controls after screening for GC in future studies. Another
limitation of the study is that the applicability of our study ﬁndings
to other ethnic groups. We investigated the plasma KP-54 levels in
Turkish caucasian population. However comparison of other ethnic
populations in terms of importance of plasma KP-54 in GC patients
need to be clariﬁed. The gender sizes were also different between
patient and control groups in our study. Pita J et al.14 pointed out
adult and obese females showed higher KP-54 levels in plasma.
Therefore, equalization of the gender and BMI are also needed infuture studies. Finally, the sensitivity of the test needs improve-
ments. Additional proteins will be included in the bioassay. These
proteins will be selected to be encoded by genes overexpressed in
GC. And, tumor and adjacent normal tissue expressions of KiSS-1
gene, protein and its receptor need to be determined in order to
conclude reﬂection KP-54 tissue levels to the plasma.
In conclusion of our preliminary results, preoperative plasma
KP-54 levels in GCwere increased with respect to plasma levels of
healthy controls. Further prospective evaluation of plasma KP-54
levels, in GC with larger study groups using other validation tests
and comparison with tissue expressions of KiSS-1 and its receptor
are needed, to emerge its clinical value in GC.
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